ctDNA Testing After Neoadjuvant Chemotherapy and Radical Cystectomy Predicts Recurrence Risk in Patients with MIBC By Ogkologos - May 21, 2026 174 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the TOMBOLA study Source RELATED ARTICLESMORE FROM AUTHOR Patient Guide in Soft Tissue Sarcoma Now Available Also in Ukrainian Adjuvant Pembrolizumab Continues to Demonstrate Benefit in DFS and OS Among Patients with ccRCC ESMO Welcomes European Parliament (EP) report on Psychosocial Risks (PSR) at Work as a Key Step towards Protecting the Cancer Workforce and Ensuring High-Quality... MOST POPULAR Trial Results Support Adding Daratumumab to Initial Treatment for Multiple Myeloma January 19, 2024 Doctor Wipes Away The Debt Of 200 Cancer Patients January 6, 2021 Speaking with One Cancer Voice for cancer patients in England March 29, 2023 Hiding in plain sight: How we can use immune cells to... February 9, 2023 Load more HOT NEWS High Risk of BCSM at 20 Years in Men with Hormone... Genomic and Immunophenotypic Heterogeneity of Acquired Resistance to Immune Checkpoint Inhibitors... Development of Secondary T-Cell Cancers After the Use of CAR T-Cells... A toolkit to address disparities in digitally enabled oncology trials
